Centre d'évaluation Thérapeutique, Dr LACOMBLEZ
Paris, 75013, France
NCT Number: NCT01984957
To isolate biomarkers of ALS in muscle
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Paris, 75013, France
At present, there is no validated biological diagnostic marker for amyotrophic lateral sclerosis (ALS). The main objective of the study is to isolate a set of genes that are specifically dysregulated in muscle from ALS patients.
Gene profiling in muscle will be compared between ALS patients and patients with other motor neuron diseases (SMA and SBMA)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
open muscular biopsy of the deltoid under local anaesthesia
Time frame: day 1
Gene expression levels in muscle as determined By microarrays (transcriptome analysis)
Time frame: day 1
Severity of muscle denervation as determined by histological analysis of muscle
Time frame: day 1
ALSFRS-R, Manual Muscle Testing and Slow Vital Capacity
Assistance Publique - Hôpitaux de Paris
Other
Differential Study of Muscle Transcriptome in Patients With Neuromuscular Disease and Control Subjects
Acronym: TRANE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04259255
ALS, Amyotrophic Lateral Sclerosis
Phoenix, Arizona, United States
View Trial DetailsNCT05508074
ALS, Amyotrophic Lateral Sclerosis
Bron, France
View Trial DetailsNCT02795897
ALS, Amyotrophic Lateral Sclerosis
Los Angeles, California, United States
View Trial DetailsNCT01363401
ALS, Amyotrophic Lateral Sclerosis
Seoul, South Korea
View Trial Details